Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Guidelines aim to establish state-regulated veterinary blood banks
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
This strategic investment strengthens Cohance's integrated oligonucleotide platform
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated